Research programme: NF-kappa B/IKK inhibitors - Nereus PharmaceuticalsAlternative Names: NPI-1342; NPI-1387; NPI-1390
Latest Information Update: 16 Jan 2014
At a glance
- Originator Nereus Pharmaceuticals
- Class Diterpenes; Small molecules
- Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Inflammation